CN112870380B - Bpoz基因在制备治疗过度炎症反应性疾病的药物中的应用 - Google Patents
Bpoz基因在制备治疗过度炎症反应性疾病的药物中的应用 Download PDFInfo
- Publication number
- CN112870380B CN112870380B CN202110162526.XA CN202110162526A CN112870380B CN 112870380 B CN112870380 B CN 112870380B CN 202110162526 A CN202110162526 A CN 202110162526A CN 112870380 B CN112870380 B CN 112870380B
- Authority
- CN
- China
- Prior art keywords
- bpoz
- caspase
- mice
- flag
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/53—Ligases (6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
- C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110162526.XA CN112870380B (zh) | 2021-02-05 | 2021-02-05 | Bpoz基因在制备治疗过度炎症反应性疾病的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110162526.XA CN112870380B (zh) | 2021-02-05 | 2021-02-05 | Bpoz基因在制备治疗过度炎症反应性疾病的药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112870380A CN112870380A (zh) | 2021-06-01 |
CN112870380B true CN112870380B (zh) | 2021-10-08 |
Family
ID=76055870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110162526.XA Active CN112870380B (zh) | 2021-02-05 | 2021-02-05 | Bpoz基因在制备治疗过度炎症反应性疾病的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112870380B (zh) |
-
2021
- 2021-02-05 CN CN202110162526.XA patent/CN112870380B/zh active Active
Non-Patent Citations (4)
Title |
---|
BPOZ抑制乳腺癌细胞系增殖的初步研究;王鹏皓 等;《军事医学》;20160425;第40卷(第4期);第308-310,330页 * |
BTB-ZF transcriptional regulator PLZF modifies chromatin to restrain inflammatory signaling programs;Sadler,AJ等;《PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA》;20150203;第112卷(第5期);第1535-1540页 * |
Guillamot, M.等.The E3 ubiquitin ligase SPOP controls resolution of systemic inflammation by triggering MYD88 degradation.《NATURE IMMUNOLOGY》.2019,第20卷(第9期),第1196-1207页. * |
The E3 ubiquitin ligase SPOP controls resolution of systemic inflammation by triggering MYD88 degradation;Guillamot, M.等;《NATURE IMMUNOLOGY》;20190812;第20卷(第9期);第1196-1207页 * |
Also Published As
Publication number | Publication date |
---|---|
CN112870380A (zh) | 2021-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019014733A (ja) | Tnfスーパーファミリー受容体に対するスプライス切替オリゴマーならびに疾病治療における該オリゴマーの使用 | |
WO2006129784A1 (ja) | インターフェロン-α制御剤 | |
CN111978408B (zh) | 靶向IKKβ的短肽及其在炎症性疾病中的应用 | |
EP2648761A1 (en) | Cancer gene therapy using nucleic acids encoding us28 and g-protein | |
Wang et al. | Upregulation of KSRP by miR‐27b attenuates schistosomiasis‐induced hepatic fibrosis by targeting TGF‐β1 | |
Pohóczky et al. | Discovery of novel targets in a complex regional pain syndrome mouse model by transcriptomics: TNF and JAK-STAT pathways | |
KR20100029079A (ko) | Gpr12의 저해로 인지 질환을 치료하는 방법 | |
You et al. | Ablation of NLRP3 inflammasome attenuates muscle atrophy via inhibiting pyroptosis, proteolysis and apoptosis following denervation | |
Zhang et al. | The emerging roles of Pellino family in pattern recognition receptor signaling | |
De Logu et al. | miRNA-203b-3p induces acute and chronic pruritus through 5-HTR2B and TRPV4 | |
CN112870380B (zh) | Bpoz基因在制备治疗过度炎症反应性疾病的药物中的应用 | |
US9068984B2 (en) | Compositions and methods for treatment of neuropathic pain | |
US20120045773A1 (en) | Cell adhesion inhibitor and applications thereof | |
US7482323B2 (en) | Intracellular interleukin-1 receptor antagonist and uses thereof | |
US20080045699A1 (en) | Interleukin-1 Related Gene and Protein | |
Li et al. | RETRACTED ARTICLE: Long Noncoding RNA H19 Induces Neuropathic Pain by Upregulating Cyclin-Dependent Kinase 5-Mediated Phosphorylation of cAMP Response Element Binding Protein | |
KR101433794B1 (ko) | 프로그래뉼린 억제제를 유효성분으로 함유하는 골다공증 예방 또는 치료용 조성물 | |
WO2013070563A1 (en) | Treatment of autoimmune and inflammatory disorders by inhibition of blimp-1 | |
KR101774465B1 (ko) | 암 치료 표적 Sirt2 및 그를 사용하여 암 치료제를 스크리닝하는 방법 | |
US20150018225A1 (en) | Cell adhesion inhibitor, cell proliferation inhibitor, and method and kit for examining cancer | |
EP1902729A1 (en) | Int6 PROTEIN INVOLVED IN HYPOXIA STRESS INDUCTION AND USE THEREOF | |
WO2017126655A1 (ja) | 疼痛の予防または治療用医薬組成物およびRobo4を用いる疼痛抑制物質のスクリーニング方法 | |
CN115300628A (zh) | Na/K-ATPaseα3在治疗肥胖及相关疾病中的应用 | |
Najm et al. | THU0081 MIR-17-5P REDUCES INFLAMMATION AND BONE EROSIONS IN COLLAGEN INDUCED ARTHRITIS MICE AND DIRECTLY TARGETS THE JAK-STAT PATHWAY IN RHEUMATOID ARTHRITIS FIBROBLAST-LIKE SYNOVIOCYTES. | |
JP2023511717A (ja) | 治療用タンパク質のリガンド媒介性送達およびその使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Wei Congwen Inventor after: Wan Luming Inventor after: Zhong Hui Inventor after: Zhang Yanhong Inventor after: Huang Linfei Inventor after: Yang Xiaopan Inventor before: Wei Congwen Inventor before: Zhong Hui Inventor before: Wan Luming Inventor before: Zhang Yanhong Inventor before: Huang Linfei Inventor before: Yang Xiaopan |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |